Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

The Pathological Diagnosis of Mesothelioma: New Recommendations- An international team of researchers says it is time to refine the pathological diagnosis of mesothelioma. They are recommending a list of changes they say could make the process more effective. Mesothelioma is a deadly cancer caused by asbestos exposure. Under current pathology guidelines, it falls into just three categories. But the research team says those guidelines do not give doctors enough information. They recommend updates to make the pathological diagnosis of mesothelioma more specific.  Understanding Mesothelioma Pathology Pathologists study body tissue, fluids, and cells that are surgically removed. The pathological diagnosis of mesothelioma involves looking at cells under a microscope. Cells can then be put into a category.  About three quarters of mesothelioma cases are epithelioid. Epithelioid mesothelioma is … Continue reading The Pathological Diagnosis of Mesothelioma: New Recommendations »

Step Counts for Cancer Prognosis: Could it Work for Mesothelioma?- Cancer researchers in New York are exploring the concept of using step counts for cancer prognosis. If further studies back it up, the technique might help predict outcomes for people with mesothelioma. The new study involved people with non-small cell lung cancer. The patients wore commercial fitness trackers so doctors could see how much they walked.  The researchers compared step levels with treatment outcomes. They concluded that there is value to using step counts for cancer prognosis. It may even be more effective than some more traditional methods for predicting survival. Cancer Prognosis and Chemoradiotherapy Mesothelioma survival usually depends on how well patients respond to standard treatments. Healthier, more active cancer patients tend to have better outcomes.  Chemotherapy and radiation … Continue reading Step Counts for Cancer Prognosis: Could it Work for Mesothelioma? »

Risk for Malnutrition Among Older Mesothelioma Patients- A new study out of Brazil suggests that many older mesothelioma patients may be at risk for malnutrition and the problems that go with it.  The study included more than 4,500 Brazliian cancer patients from 45 hospitals. They were evaluated for their nutritional status, nutritional risk, and nutrition-related symptoms. Among the 25% of cancer patients over 65, more than half faced a moderate to severe risk for malnutrition. The findings suggest it is a problem hospitals should identify and address early for the best mesothelioma treatment outcomes.  Mesothelioma and Nutritional Status As with other types of cancer, nutrition has an affect on the treatment of people with mesothelioma.  An Australian study of pleural mesothelioma patients earlier this year found that … Continue reading Risk for Malnutrition Among Older Mesothelioma Patients »

Large Study Finds Treatment Combination Leads to Long-Term Mesothelioma Survival- There is more evidence that surgery and intraperitoneal chemotherapy can lead to long-term mesothelioma survival. The news comes from an Australian study of more than 1,200 cancer patients. The study finds that one in five peritoneal mesothelioma patients who had this treatment combination were still alive 10 years later.  Peritoneal Cancer Survival with Surgery  Peritoneal cancers occur on the lining of the abdomen. Peritoneal mesothelioma starts on this peritoneal membrane. Some other peritoneal cancers start elsewhere in the body and spread to the peritoneum. The new Australian study analyzed the cases of peritoneal cancer patients who had cytoreductive surgery between 1996 and 2018. Cytoreductive surgery aims to remove as much of the cancer as possible. Past studies have found that … Continue reading Large Study Finds Treatment Combination Leads to Long-Term Mesothelioma Survival »

Spotting the BAP1 Gene Mutation in Mesothelioma Patients- New guidelines may make it easier to tell which mesothelioma patients contracted the disease because of a BAP1 gene mutation. The knowledge could have an impact on mesothelioma treatment planning. BAP1 stands for BRCA associated protein-1. People who have an inherited BAP1 gene mutation face a higher risk for several conditions, including malignant mesothelioma.  Very few mesothelioma patients have the mutation and gene testing is not routine. So researchers at a top US cancer center have developed a set of screening criteria. The criteria may help predict which mesothelioma patients could benefit from genetic testing. Testing for the Altered Gene Mesothelioma is just one of the conditions associated with the inherited BAP1 gene mutation. People with this condition are also … Continue reading Spotting the BAP1 Gene Mutation in Mesothelioma Patients »

Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels- Patients with the rarest mesothelioma subtypes tend to experience shorter mesothelioma survival. Now, new mesothelioma research suggests that may have something to do with a protein called PD-L1. French researchers studied the PD-L1 levels in the tumors of 214 mesothelioma patients. They compared the levels with each patient’s subtype and their treatment outcome.  The results may help explain cases of shorter mesothelioma survival, especially among patients with sarcomatoid or biphasic mesothelioma subtypes.  PD-L1 Levels and Shorter Mesothelioma Survival Programmed death ligand 1 (PD-L1) is one of the proteins that helps mesothelioma cells and other cancers “hide” from the immune system.  Normally, the immune system finds and destroys renegade cells. But if a patient’s mesothelioma tumor expresses higher amount of PD-L1, … Continue reading Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels »

Mesothelioma Survival Rates Have Remained Flat for Decades- Mesothelioma survival rates have stayed steady for decades, even though treatments are improving. According to more than 25 years worth of data from the National Mesothelioma Virtual Bank, people with malignant mesothelioma live a median of 15 months. That number has changed little since 1990. Charting Mesothelioma Patients Over Time Researchers from several major US cancer centers compiled the new report. The goal was to chart mesothelioma survival rates over time and identify factors that impact them. The group evaluated mesothelioma survival rates from 888 cases of pleural and peritoneal mesothelioma in the NMVB. The NMVB houses information on more than 1400 mesothelioma cases diagnosed between 1990 and 2017. Overall mesothelioma survival rates stayed right around 15 months. But there … Continue reading Mesothelioma Survival Rates Have Remained Flat for Decades »

Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages- New research shows adjuvant radiotherapy is most likely to help pleural mesothelioma patients in the early stages of the disease. By the time mesothelioma is at Stage III or Stage IV, adjuvant radiotherapy is unlikely to improve survival. Researchers at MD Anderson Cancer Center in Texas conducted the study on more than 2,500 pleural mesothelioma patients. Their results appear in the most recent issue of the Journal of Thoracic Disease. The study could help mesothelioma patients and doctors make more informed choices about their care. Defining the Stages of Pleural Mesothelioma The four stages of mesothelioma relate to the severity of the cancer and how far it has spread. In Stage I mesothelioma, the tumor is confined to the pleural … Continue reading Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages »

Minimally Invasive Mesothelioma Diagnosis from Lung Fluid- Minimally invasive mesothelioma diagnosis with lung fluid may be just as effective as a tissue biopsy. That’s according to Australian mesothelioma researchers. Australia was once one of the biggest producers of asbestos and now has some of the highest mesothelioma rates in the world. It is also home to high-level mesothelioma research. In the latest study, scientists ran a meta-analysis comparing surgical biopsy with a minimally invasive mesothelioma diagnosis tool called cytology. Their conclusion is that surgery may not always be necessary to diagnose malignant mesothelioma. Tissue Versus Lung Fluid Malignant mesothelioma is a fatal cancer caused by exposure to asbestos. It is challenging to diagnose because the symptoms are often vague and similar to other less serious conditions. Doctors … Continue reading Minimally Invasive Mesothelioma Diagnosis from Lung Fluid »

Systemic Inflammation Linked to Shorter Mesothelioma Survival- Mesothelioma patients whose bodies respond to the illness with systemic inflammation are less likely to survive. Chinese researchers have linked a measure of systemic inflammation called SII to shorter survival in people with pleural mesothelioma. The new study involved 97 people with confirmed malignant mesothelioma. It suggests that SII could be a simple, non-invasive way to determine mesothelioma prognosis. What is SII? SII stands for “systemic immune-inflammation index”. When a body is under stress, such as when it is fighting mesothelioma, the innate immune system kicks into action. Certain kinds of white blood cells and proteins are released. The result is systemic inflammation. SII can be determined with a blood test. The test measures the levels of white blood cells … Continue reading Systemic Inflammation Linked to Shorter Mesothelioma Survival »